Purpose We performed a randomized trial to compare the efficacy and toxicity of a new dose
of flutamide (500 mg QD) with the currently recommended dose (250 mg q8h) in the …

OBJECTIVE To investigate the efficacy of low‐dose flutamide (125 mg twice daily) in the
treatment of prostate‐specific antigen (PSA) recurrence after definitive treatment with radical …

Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or
binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen …

Background: Some authors have recently reported that maximum androgen block (MAB), in
which the nonsteroidal anti–androgen, flutamide, is used together with conventional …

Objective: In a multicenter study, 905 patients with newly diagnosed advanced prostate
cancer treated with flutamide were followed for safety and side effects. Methods: Flutamide …

Background: In a recent study by the Casodex Combination Study Group, USA, patients in a
flutamide (750mg/day) plus LH‐RH agonist group showed a high treatment failure rate …

PURPOSE To evaluate the effect of discontinuation of the antiandrogen, flutamide, in
patients with metastatic prostate cancer who are progressing on hormonal therapy …

OBJECTIVES: The objective of this study was to evaluate efficacy, safety, and dose-
response profiles of four dosing schemes of flutamide over 24 weeks. METHODS: Patients …

Abstract Flutamide (250 mg. orally 3 times daily) yielded a subjective response in 5 of 25
fully evaluable patients with hormone-resistant prostatic cancer. Four additional patients had …

Backgroound The best treatment for patients with “hormone-refractory” metastatic prostate
cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed …